Xenetic Biosciences, Inc. Strengthens Expertise to Advance XCART Development Program with Appointment of Cell Therapy Expert, Maksim Mamonkin, Ph.D. to Scientific Advisory Board Feb 13, 2020
Xenetic Biosciences, Inc. to Present at Noble Capital Markets' 16th Annual Investor Conference Feb 11, 2020
Xenetic Biosciences, Inc. Announces Publication of Data from Partner's Phase 1/2 Study Evaluating Program Leveraging Polyxen(R) Platform Technology Jan 14, 2020
Xenetic Biosciences, Inc. Reports Third Quarter 2019 Financial Results and Provides Corporate Update Nov 15, 2019
Xenetic Biosciences, Inc. to Present at the Dawson James Securities 5th Annual Small Cap Growth Conference Oct 29, 2019
Xenetic Biosciences, Inc. Reports Second Quarter 2019 Financial Results and Provides Corporate Update Aug 15, 2019
Xenetic Biosciences, Inc. Closes $15.0 Million Underwritten Public Offering and Completes Acquisition of Innovative CAR T Technology Platform Jul 22, 2019
Xenetic Biosciences, Inc. (Nasdaq: XBIO) Announces Pricing of $15.0 Million Underwritten Public Offering Jul 17, 2019
